Page 7 - Data Presented News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Diskussion Der Oberste Gerichtshof (OGH) hat im Rechtsstreit von Max Schrems mit Facebook den Europäischen Gerichtshof (EuGH) angerufen, um in einzelnen Punkten Klarheit zu schaffen. Die Fragen werfen Zweifel an der Rechtmäßigkeit der Datennutzung durch Facebook bei allen EU-Nutzern auf. So soll geklärt werden, ob die Nutzer tatsächlich - wie vom Social-Media-Konzern argumentiert - einen „Vertrag“ abschließen, weswegen die Datenschutz-Grundverordnung (DSGVO) nur eingeschränkt zutreffe. Schrems ist überzeugt, dass der Online-Gigant im Umgang mit den Daten seiner Benutzer gegen d...

Share: Post hoc analyses by estimated on-treatment serum EPA levels in the VASCEPA group suggest potentially reduced incidence of new heart failure and new heart failure requiring hospitalization with higher achieved serum EPA levels Amarin to Webcast Discussion of Data Presented at ACC.21 Monday, May 17, 2021 at 4:30 p.m., Eastern Time DUBLIN, Ireland and BRIDGEWATER, N.J., May 15, 2021 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced the presentation of REDUCE-IT ® HEART FAILURE (HF) at ACC.21, the American College of Cardiology's 70th Annual Scientific Session, b...

uniQure Inc.: uniQure Presents HOPE-B Clinical Data Demonstrating Clinical Benefit in Hemophilia B Patients with Pre-existing Antibodies to AAV5 Vector ~ Further Supports Potential for AAV5 Gene Therapies to be Viable Treatments in Nearly All Patients -- ~ Data Presented at the American Society of Gene & Cell Therapy (ASGCT) Annual Meeting ~ LEXINGTON, Mass. and AMSTERDAM, May 13, 2021showing clinical benefit in hemophilia B patients with pre-existing neutralizing antibodies (NAbs) to AAV5, and no relationship between AAV5 NAbs and the tolerability of the therapy. The data were featured on We...

~ Further Supports Potential for AAV5 Gene Therapies to be Viable Treatments in Nearly All Patients -- ~ Data Presented at the American Society of Gene & Cell Therapy (ASGCT) Annual Meeting ~ LEXINGTON, Mass. and AMSTERDAM, May 13, 2021 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, yesterday presented 26-week clinical data from the pivotal, Phase III HOPE-B gene therapy trial of etranacogene dezaparvovec showing clinical benefit in hemophilia B patients with pre-existing neutralizing...

ORIC Pharmaceuticals Reports First Quarter 2021 Financial Results and Operational Update Lead program ORIC-101 on track for two initial Phase 1b data readouts in 2021 Three IND/CTA filings for ORIC-533, -944, and -114 expected in 2021 SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, May 06, 2021 (GLOBE NEWSWIRE) — ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today reported financial results and operational updates for the quarter ended March 31, 2021. “We continue to make steady ...